8 research outputs found
European Expert Opinion on ANT-DBS therapy for patients with drug-resistant epilepsy (a Delphi consensus)
Introduction: Although deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) represents an established third-line therapy for patients with drug-resistant focal epilepsy, guiding reports on practical treatment principles remain scarce. Methods: An Expert Panel (EP) of 10 European neurologists and 4 neurosurgeons was assembled to share their experience with ANT-DBS therapy. The process included a review of the current literature, which served as a basis for an online survey completed by the EP prior to and following a face-to-face meeting (Delphi method). An agreement level of >= 71 % was considered as consensus. Results: Out of 86 reviewed studies, 46 (53 %) were selected to extract information on the most reported criteria for patient selection, management, and outcome. The Delphi process yielded EP consensus on 4 parameters for selection of good candidates and patient management as well as 7 reasons of concern for this therapy. Since it was not possible to give strict device programming advice due to low levels of evidence, the experts shared their clinical practice: all of them start with monopolar stimulation, 79 % using the cycling mode. Most (93 %) EP members set the initial stimulation frequency and pulse width according to the SANTE parameters, while there is more variability in the amplitudes used. Further agreement was achieved on a list of 7 patient outcome parameters to be monitored during the follow-up. Conclusions: Although current evidence is too low for definite practical guidelines, this EP report could support the selection and management of patients with ANT-DBS
European Expert Opinion on ANT-DBS therapy for patients with drug-resistant epilepsy (a Delphi consensus)
INTRODUCTION: Although deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) represents an established third-line therapy for patients with drug-resistant focal epilepsy, guiding reports on practical treatment principles remain scarce. METHODS: An Expert Panel (EP) of 10 European neurologists and 4 neurosurgeons was assembled to share their experience with ANT-DBS therapy. The process included a review of the current literature, which served as a basis for an online survey completed by the EP prior to and following a face-to-face meeting (Delphi method). An agreement level of ≥71 % was considered as consensus. RESULTS: Out of 86 reviewed studies, 46 (53 %) were selected to extract information on the most reported criteria for patient selection, management, and outcome. The Delphi process yielded EP consensus on 4 parameters for selection of good candidates and patient management as well as 7 reasons of concern for this therapy. Since it was not possible to give strict device programming advice due to low levels of evidence, the experts shared their clinical practice: all of them start with monopolar stimulation, 79 % using the cycling mode. Most (93 %) EP members set the initial stimulation frequency and pulse width according to the SANTE parameters, while there is more variability in the amplitudes used. Further agreement was achieved on a list of 7 patient outcome parameters to be monitored during the follow-up. CONCLUSIONS: Although current evidence is too low for definite practical guidelines, this EP report could support the selection and management of patients with ANT-DBS.status: publishe
Aspectos atuais da herniorrafia no idoso
A hérnia no paciente maior de 65 anos, ainda hoje, admite questionamentos quanto à sua etiologia, evolução e manejo. As condições clínicas do paciente e a debilidade dos tecidos da parede abdominal multiplicam as dificuldades inerentes à herniorrafia. O manejo cirúrgico apropriado é o reparo eletivo precoce, que apresenta índices limitados de complicações, sendo de maneira geral uma operação segura. Em casos de emergência, tentativas de desencarceramento estão contra-indicadas, já que em idosos a sintomatologia de sepse intra-abdominal inicia1 é frustra. O tratamento cirúrgico deve ser preconizado, pois nas operações de emergência a morbi/mortalidade da herniorrafia está significativamente elevada. A presente revisão pretende analisar os fatores envolvidos no sucesso da herniorrafia no idoso, destacando os aspectos atuais do pré, trans e pós-operatório
BRCA2 Polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers
Q1Q1Artículo Original1-10Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) has been found to be associated with
small increased risks of breast cancer. However, it is not clear to what extent linkage disequilibrium with fully pathogenic
mutations might account for this association. There is scant information about the effect of K3326X in other hormonerelated cancers.
Methods: Using weighted logistic regression, we analyzed data from the large iCOGS study including 76 637 cancer case
patients and 83 796 control patients to estimate odds ratios (ORw) and 95% confidence intervals (CIs) for K3326X variant
carriers in relation to breast, ovarian, and prostate cancer risks, with weights defined as probability of not having a
pathogenic BRCA2 variant. Using Cox proportional hazards modeling, we also examined the associations of K3326X with
breast and ovarian cancer risks among 7183 BRCA1 variant carriers. All statistical tests were two-sided.
Results: The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10-6) and invasive ovarian
cancer (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10-3). These associations were stronger for serous ovarian cancer and for
estrogen receptor–negative breast cancer (ORw = 1.46, 95% CI = 1.2 to 1.70, P = 3.4x10-5 and ORw = 1.50, 95% CI = 1.28 to 1.76,
P = 4.1x10-5, respectively). For BRCA1 mutation carriers, there was a statistically significant inverse association of the K3326X
variant with risk of ovarian cancer (HR = 0.43, 95% CI = 0.22 to 0.84, P = .013) but no association with breast cancer. No
association with prostate cancer was observed.
Conclusions: Our study provides evidence that the K3326X variant is associated with risk of developing breast and ovarian
cancers independent of other pathogenic variants in BRCA2. Further studies are needed to determine the biological
mechanism of action responsible for these associations